Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2093)	1/7/2008 11:23:35 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

VRUS is making an all time H as it trade above its Oct5 & Nov8 Hs of $14.73 <g> bigcharts.marketwatch.com It announced the preliminary results of a 4-week PI to evaluate oral dose levels of its R7128 in combination with Pegasys in 50 patients chronically infected with HCV genotype 1. The study demonstrated potent short-term antiviral activity and was generally safe and well-tolerated. (85% of patients receiving R7128 1500mg and Pegasys plus Copegus achieved undetectable HCV RNA levels following 4 weeks of treatment with safety and tolerability comparable to placebo.) VRUS' R7128 is a prodrug of PSI-6130, a cytidine nucleoside analogue polymerase inhibitor of HCV that is being developed in collaboration with Roche. VRUS had a good 4thQ (Sep) with revenues up to 8M vs, 0.54M in 2006 & trimming its loss to $0.08 vs. $0.17 But VRUS is going to have a little harder time in showing similar % improvements on the 1stQ (Dec) since in 2007 it reported $8.1M in revenues vs. $0.83M in 2006 & the earnings were $0.19 on the black vs, loss of $0.15 in 2006 Although the insiders reportedly hold > 35%; the float is < 9M & VTUS doesn't have significant LTD, with expected loss in 2008 & 2009 of > $1 each & the present general market mood, it seems the stock will close today's little UG before it can continue any UM.<g> bigcharts.marketwatch.com Bernard